

## PRESS RELEASE

Of interest to editors and journalists covering:  
Biotech, Medical Research, Pharmaceuticals, Public Companies, TX Business News

Dr. Herbert A. Fritsche, Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at M.D. Anderson Cancer Center accepts position as Chairman of the Scientific Advisory Board of Health Discovery Corporation

WACO, Texas - Jan. 27, 2004 /Send2Press Newswire/ -- Health Discovery Corporation (OTC Bulletin Board: HDVY), a systems biology oriented biomarker and pathway discovery company, which uses proprietary advanced mathematical platforms, such as Fractal Genomics Modeling (FGM) techniques, to help identify and characterize diagnostic targets and therapeutic drug candidates from complex genomic, proteomic and clinical data sets, is honored that Dr. Herbert Fritsche of M.D. Anderson Cancer Center has accepted the position as Chairman of the Company's Scientific Advisory Board joining other distinguished members including Dr. Kary Mullis, recipient of the Nobel Prize for his invention of PCR.

Dr. Herbert A. Fritsche is Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center in Houston, Texas. During his 35 years at M.D. Anderson Cancer Center, Dr. Fritsche has focused his research activities on the development and validation of cancer diagnostics. Dr. Fritsche has participated in the validation and FDA clearance process for every commercial serum tumor marker product currently in use in the United States.

Dr. Fritsche has served as President of the Clinical Ligand Assay Society (CLAS) and on various committees for both the CLAS and the American Association for Clinical Chemistry (AACC). He is a fellow of the National Academy of Clinical Biochemistry and was awarded the National Award for Contributions in Education by the AACC; the Outstanding Clinical Chemist Award by the Texas Section, AACC; a Dean's Excellence Award for the University of Texas Graduate School of Biomedical Science; a Distinguished Scientist Award from the CLAS; and the Johnson and Johnson Award for Outstanding Research and Contributions to Clinical Biochemistry from the National Academy of Clinical Biochemistry.

Dr. Fritsche currently serves on the Expert Panel for developing Tumor Marker Practice Guidelines for the American Society of Clinical Oncology, and the Laboratory Practice Guidelines Committee for the National Academy of Clinical Biochemistry. In addition, he serves on the Editorial Board of six international scientific journals.

Dr. Fritsche serves as a consultant/advisor to the National Cancer Institute and for some major international diagnostic companies and biotech start-up companies. Dr. Fritsche has published over 170 peer reviewed scientific papers, invited articles and book chapters. Dr. Fritsche holds 3 patents and has 2 other applications on file. He has lectured extensively for many years at international and national meetings.

"We are extremely honored that Dr. Herbert Fritsche, one of the worlds leading experts on tumor biomarkers, with his vast and unique experience has agreed to become Chairman of our Scientific Advisory Board," said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. "In addition to providing unparalleled scientific expertise, Dr. Fritsche will bring significant commercialization experience having participated in the validation and FDA clearance process for every commercial serum tumor marker product currently in use in the United States."

Dr. Fritsche commented, "I believe that the systems biology approach to biomarker and pathway discovery will provide the diagnostic and drug targets that will advance patient care to the point where personalized medicine will become a reality." Dr. Fritsche continued "I look forward to working with Dr. Barnhill and the distinguished group of experts he has assembled to achieve

the goal of advancing scientific discovery and commercializing the next generation of diagnostic markers and drug targets." For more information contact Robert S. Braswell IV of Health Discovery Corporation +1-866-953-9031 or Info@dwcell.com .

This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

MEDIA CONTACT:

Robert S. Braswell IV  
Of Health Discovery Corporation  
+1-866-953-9031  
Info@dwcell.com

(OTC BB: HDVY)

# # #

[ source of news = Health Discovery Corporation ]  
ref: [http://www.send2press.com/2archive/2004/pr\\_04\\_0127-hdvy.txt](http://www.send2press.com/2archive/2004/pr_04_0127-hdvy.txt)  
[http://www.send2press.com/2archivePDF/pr\\_04\\_0127-hdvy.pdf](http://www.send2press.com/2archivePDF/pr_04_0127-hdvy.pdf)

-----  
\*IMPORTANT NOTE TO MEDIA:  
to reach the organization releasing this news, please contact:  
Info@dwcell.com

If used for publication, please send specimen copy.

-----  
S2PPRN-R/7c/ TX / Waco, Texas / Copr. (c) 2004 Send2Press.

This release was issued on behalf of the above organization by Send2Press(tm), a unit of Neotrope(R). <http://www.Send2Press.com> .